本文選題：單倍體相合異基因造血干細胞移植 + 移植物抗宿主病�。� 參考：《中國實驗血液學雜志》2016年03期

【摘要】：目的:進一步總結單倍體相合造血干細胞移植的臨床經(jīng)驗,并探討其療效。方法:比較83例單倍體移植和本移植中心同期73例同胞全相合移植的療效,并分析影響移植后生存的相關危險因素。結果:單倍體移植組與全相合移植組在造血重建、發(fā)生移植物抗宿主病(GVHD)、總生存(OS)、無病生存(DFS)、移植后復發(fā)及移植相關死亡率(TRM)等方面均無顯著性差別;多因素分析顯示,移植前的疾病狀態(tài)、移植后復發(fā)及出現(xiàn)Ⅲ-Ⅳ度急性GVHD是影響移植后生存的危險因素,相對風險(RR)分別為3.1(95%CI,1.7-5.4),3.5(95%CI,2.0-6.2)和2.5(1.4-4.6)(P0.05)。結論:應用現(xiàn)有的移植體系進行單倍體移植的療效與同胞全相合移植相當,移植前的疾病狀態(tài)及移植后是否出現(xiàn)重度急性GVHD對移植后患者的生存具有重要意義。
[Abstract]:Objective: to summarize the clinical experience of haploid compatible hematopoietic stem cell transplantation (HSCT) and to explore its curative effect. Methods: 83 cases of haploid transplantation and 73 cases of sibling complete transplantation in the same period were compared, and the risk factors affecting survival after transplantation were analyzed. Results: there were no significant differences in hematopoietic reconstitution, GV HDV, total survival, disease-free survival (DFSN), post-transplant recurrence and transplantation-related mortality (TRM) between the haploid transplantation group and the homozygous transplantation group. The state of disease before transplantation, recurrence after transplantation and occurrence of grade 鈪，

本文編號：1887969